Condition
Atypical Ductal Hyperplasia
Total Trials
7
Recruiting
0
Active
0
Completed
3
Success Rate
75.0%-12% vs avg
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
Termination Rate
14.3%
1 terminated out of 7 trials
Success Rate
75.0%
-11.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results75% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (4)
P 2 (1)
Trial Status
Completed3
Unknown2
Terminated1
Withdrawn1
Trial Success Rate
75.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (7)
Showing 7 of 7 trials
NCT02928978Phase 2Completed
Ruxolitinib for Premalignant Breast Disease
NCT03868475Not ApplicableWithdrawn
Comparing Vacuum-Assisted Percutaneous Excision to Open Surgical Excision for Borderline or High-Risk Breast Lesions
NCT05932758Not ApplicableUnknownPrimary
Excisional Vacuum-Assisted Breast Biopsy
NCT05868252Unknown
Molecular Analysis of the Sloane Project
NCT03505372Not ApplicableTerminatedPrimary
Role of Contrast Enhanced Spectral Mammography to Predict Upgrade Rates of Biopsy Proven Atypical Ductal Hyperplasia
NCT01052740Completed
X-Ray Mammography Standard of Care Protocol
NCT00620087Not ApplicableCompleted
Molecular Breast Imaging in Women With Atypia and LCIS
Showing all 7 trials